Novel evidence of microglial immune response in impairment of XXXX of CNS.

@entity778 @entity32 @entity8929 @entity198 @entity548 @entity8843 @entity19 @entity635 @entity5780 @entity5779 @entity1618 @entity777 @entity1800 @entity1235 @entity281 @entity779 @entity637 @entity221
UNASSIGNED: Dengue, the most rampant zoonotic @entity1800 in tropics, contributes to 14% of acute @entity221 cases globally. @entity198 in primary @entity779 , with/without @entity548 has been reported occasionally. Our study presents novel evidence for this rarity at the molecular level. @entity19 microglia (BV2) were @entity778 (DENV) serotypes (1-4) and their immune response was evaluated. Gene expressions of @entity637 , @entity1618 , IFN-y, and @entity635 constituted the pro-inflammatory response, levels of @entity8929 and @entity777 represented the regulatory mechanism and changes in the levels of @entity8843 , @entity5780 , @entity1235 and @entity5779 encompassed the break-down of the blood-brain barrier (BBB). Cytokine response was studied using RT-PCR, with relative fold change assessed using     Ct method. We observed that DENV1 increased vascular permeability and trans-membrane transport, while DENV2 resulted in oxidative stress. DENV3 @entity281 presented with impaired immune response and DENV4 manifested a chaotropic response of the BBB protein genes. However, no serotype was able to breakdown the BBB, thus validating the low prevalence of @entity198 in dengue. Our study is the first reported evidence of the microglial immune response resisting the entry of DENV into the CNS. It also supports the theory that primary @entity281 results in the acute @entity32 of the microglia, and the host immune response plays a critical role in development of @entity198 .
